1 Min Read
Aug 23 (Reuters) - GlaxoSmithKline Plc : * Announces phase III study of Vercirnon in patients with moderate-to-severe
Crohn’s disease did not meet its primary endpoint * New recruitment and dosing in ongoing clinical programme has been suspended
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.